ifosfamid region hyperthermia patient advanc sarcoma phase II studi juli juli patient deep-seat advanc soft tissu sarcoma st patient ewe sarcoma ES patient OS patient chondrosarcoma ch patient univers munich protocol region hyperthermia rht ifosfamid etoposid total rht treatment rht patient pelvic extrem abdomin site mean tumor volum cc rang cc system chemotherapi patient day day mesna day rht day cycl week acut toxic pain local discomfort annular array applic AA bsd hyperthermia system bsd medic corp salt lake citi UT averag maximum system temperatur degre indic enhanc bone marrow toxic due addit rht system chemotherapi thermal map invas thermometri patient assess patient overal object respons rate complet respons cr partial respons pr favor histolog respons fhr confid limit complet respond aliv disease-fre month patient PR fhr metastat diseas month diseas month patient stabl month patient chang NC patient local tumor progress PD mean observ time patient month time-averag temperatur Ts rht treatment tumor site respond nonrespond data support activ ifosfamide-etoposid rht pretreat patient advanc sarcoma 